#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Juvenile idiopathic arthritis Cutaneous T-cell lymphoma stage II Pelizaeus-Merzbacher disease Hepato-lenticular degeneration Diffuse large B-cell lymphoma recurrent Leiomyosarcoma recurrent Bone marrow disorder White matter lesion Acromegaly Adult T-cell lymphoma/leukaemia refractory Hereditary hypophosphataemic rickets Extraskeletal ossification Neuroblastoma recurrent Pulmonary alveolar haemorrhage Peritoneal neoplasm More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Treatment Angiosarcoma non-metastatic – Trials in Disease Mantle cell lymphoma stage III – Diagnostics Hereditary neuropathic amyloidosis Gastrointestinal stromal tumour – Trials in Disease Stevens-Johnson syndrome – Life with Disease Hyperoxaluria – Life with Disease Paraneoplastic neurological syndrome – Life with Disease Adrenogenital syndrome – Trials in Disease Myelodysplastic syndrome with excess blasts – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dopamine Hydrochloride GSK5764227 Ticagrelor Defactinib Placebo Ammonium Chloride Bp Bms-986340 Bi-1808 Gallium (68Ga) ICEF15 Xp-Dc+Tl+Klh Keto-Isoleucine Calcium Chloroprocaine Hydrochloride Soya-Bean Oil Refined Panobinostat Midostaurin Gad20-209-Fsp-A2 Ganciclovir Heterodimeric Interleukin-15 Fluticasone Furoate More therapies…

    Learn about Your Condition

    Noonan syndrome Osteonecrosis of jaw Dementia with Lewy bodies Trigeminal neuralgia Lung cancer metastatic Paraesthesia Candida infection Immunodeficiency Cutaneous T-cell lymphoma Vulvar dysplasia Adrenogenital syndrome Ureteric cancer Red blood cell abnormality Peritoneal neoplasm Arteriovenous malformation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Ipilimumab
    France Germany Italy Poland Spain

  • A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • S-241656
    • Irinotecan Hydrochloride Trihydrate
    • Cetuximab
    Denmark France Italy Spain

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Vinflunine
    • Docetaxel
    • Paclitaxel
    Belgium France Germany Greece Italy The Netherlands +2

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elritercept
    • Epoetin Alfa
    Belgium Bulgaria France Germany Greece Hungary +8

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    • Topotecan Hydrochloride
    • Doxorubicin Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2

  • Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Gadoteric Acid
    Czechia France Germany Hungary Italy Poland +1

  • Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

    Recruiting

    2 1 1
    Investigated Diseases:
    • Craniocerebral injury
    Investigated Drugs:
    • Cenegermin
    Denmark Finland France Germany Italy Poland +2

  • A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Frexalimab
    Belgium Italy Spain

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • AZD5335
    • Doxorubicin Hydrochloride, Liposomal
    Belgium Czechia Denmark France Germany Greece +4

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    • Paclitaxel
    Belgium Denmark Finland France Germany Greece +5
Previous Page
1 2 3 4 5 6 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!